Search clinical trials for: Apatinib and Etoposide capsule

Total 6263 results

The Affiliated Hospital of Qingdao University

Unknown

The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy

Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

Subjects With Impaired Renal Function and Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Fudan University; The 81 Hospital of PLA

Completed

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Advanced or Metastatic Gastric Cancer

China
Ruijin Hospital

Recruiting

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Peripheral T Cell Lymphoma

China
University of Jena
Novartis Pharmaceuticals; Ludwig-Maximilians - University of Munich

Active, not recruiting

Frontline Asciminib Combination in Chronic Phase CML (CMLXI)

Chronic Myeloid Leukemia

Germany
Boehringer Ingelheim

Completed

Afatinib in Subjects With Kidney Dysfunction

Renal Insufficiency

Germany
Novartis Pharmaceuticals

Completed

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Germany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg

Healthy

United States
ShiYue Li

Unknown

Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer (CCA-MPLC)

Lung Cancer
Valduce Hospital

Unknown

PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening Program

Colon Cancer

Italy
Cancer Institute and Hospital, Chinese Academy...

Unknown

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Sarcoma
Beijing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

HER-2 Negatived Gastric Cancer

China
Samsung Medical Center
Ministry of Health, Republic of Korea

Recruiting

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Relapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid Tumor

Korea, Republic of
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Active, not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada
Fudan University

Recruiting

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Gastric Cancer | Metastasis

China
Di Wu

Recruiting

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Acral Melanoma

China
Peking University People's Hospital

Completed

Apatinib for Inoperable Advanced Chondrosarcoma (AIAC)

Efficacy | Toxicity, Drug

China
Guangzhou Institute of Respiratory Disease
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma (Spark-AL003)

Lung Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Differentiated Thyroid Carcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) (HCC)

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.

Metastatic Renal Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Unknown

A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure

Hepatocellular Carcinoma
Institut Paoli-Calmettes

Suspended

Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer (PIKHER2)

Breast Cancer

France
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) (OAIE)

Toxicity | Effect of Drug | Drug

China
Beijing Chest Hospital

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Non-small Cell Lung Cancer
Henan Cancer Hospital

Recruiting

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (CAMERA)

Small Cell Lung Carcinoma

China
Sun Yat-sen University

Recruiting

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Neoadjuvant Therapy | Apatinib | Carilizumab | Recurrent High-Grade Glioma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Relapsed Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Hepatocellular Carcinoma (HCC)

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

Colorectal Cancer

China
Shanghai Zhongshan Hospital

Unknown

Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Gastric Cancer | Chemotherapy Effect | Chemotherapeutic Toxicity

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
The Affiliated Hospital of the Chinese Academy...

Unknown

Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer

Hepatocellular Carcinoma

China
Zhejiang University

Recruiting

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma (CAPT)

Hepatocellular Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Nasopharyngeal Carcinoma | Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Molecular Targeted Therapy

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

Hepatocellular Carcinoma

China
Hubei Cancer Hospital

Enrolling by invitation

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

NSCLC

China
Peking University Cancer Hospital & Institute
Peking University First Hospital; Shanxi Province Cancer Hospital; Peking University... and other collaborators

Completed

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Breast Cancer
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Second-line Treatment

China
Qianfoshan Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Immune Checkpoint Inhibition

China
GUO WEI

Completed

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

Osteosarcoma | Metastasis

China
Tianjin Medical University Cancer Institute and...
Zhejiang Cancer Hospital; Fudan University; Liaoning Tumor Hospital & Institute; Gansu Cancer Hospital

Unknown

Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Soft Tissue Sarcoma, Adult, Stage II

China
Peking University

Unknown

To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.

GIST

China
Xuanwu Hospital, Beijing

Recruiting

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

Chordoma | Chemotherapy Effect

China
Sunshine Lake Pharma Co., Ltd.

Unknown

The Study of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH,in Healthy Subjects

Healthy

China
GlaxoSmithKline

Completed

A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval

Cancer

United States
Giuliani S.p.A
FitBiomics, Inc.

Completed

Efficacy of a Mix of Probiotics in Athletes Performance (GIU-PPA-0420)

Healthy

Italy

Search clinical trials for: Apatinib and Etoposide capsule

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations